TY  - CHAP
AU  - Ilze Strumfa
AU  - Dzeina Mezale
AU  - Boriss Strumfs
AU  - Andrejs Vanags
AU  - Arturs
Kalva
AU  - Dainis Balodis
AU  - Ilze Fridrihsone
AU  - Arnis Abolins
AU  - Janis
Gardovskis
ED  - Costin Teodor Streba
ED  - Cristin Constantin Vere
ED  - Ion Rogoveanu
Y1  - 2018-11-05
PY  - 2018
T1  - Innovative Blood Tests for Hepatocellular Carcinoma: Liquid Biopsy and Evaluation of Systemic Inflammatory Reaction
N2  - Hepatocellular carcinoma (HCC) currently ranks as the third most common cause of death. As the primary malignancy of the liver is directly related to an underlying liver condition, its incidence and profile are expected to change soon. While effective prevention programs and antiviral therapies for hepatitis B and C will lower the incidence of HCC, emerging socioeconomic issues will deliver new at-risk populations. Moreover, diagnostic techniques and protocols have undergone significant advancements. Reliance on contrast enhanced ultrasound has been re-evaluated, imaging methods being considered as sufficient diagnostic tools. Molecular characterization remains desirable, since chemotherapeutic agents still have limited applicability. In light of recent diagnostic advancements and novel therapeutic solutions, it is our belief that a comprehensive update on recent paradigm shifts and interesting upcoming developments is highly needed.
BT  - Hepatocellular Carcinoma
SP  - Ch. 3
UR  - https://doi.org/10.5772/intechopen.76599
DO  - 10.5772/intechopen.76599
SN  - 978-1-78984-274-6
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-19
ER  -